Gates Biomanufacturing Facility Announces Strategic Manufacturing Agreement with Cell Therapy Pioneer, Nkarta

The Gates Biomanufacturing Facility (GBF) today announced a continued strategic agreement with Nkarta, Inc. to manufacture clinical supply of therapeutic Natural Killer (NK) cells. As part of this collaboration, GBF will continue to manufacture NKX101, Nkarta’s clinical stage investigational NK cell therapy, in its facility on the University of Colorado Anschutz Medical Campus in Aurora, Colorado.

NKX101 is an “off-the-shelf” investigational immunotherapy currently in a Phase 1 clinical trial for patients with relapsed/refractory acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes (MDS). To produce NKX101, NK cells obtained from the peripheral blood of healthy donors are engineered with membrane-bound interleukin 15 and a chimeric antigen receptor (CAR) to enhance the targeting and killing of tumor cells. The engineered NK cells are then expanded at scale to generate an abundant supply of doses. NKX101 is not approved by regulatory authorities, and its safety and efficacy have not been established.

The Gates Biomanufacturing Facility on the CU Anschutz Medical Campus is one of the few Good Manufacturing Practice (GMP) facilities located on a major academic research and clinical campus with the capacity to manufacture both cell and protein-based therapies for academic researchers as well as biotechnology companies.

“Our partnership with the Gates Biomanufacturing Facility is an excellent fit,” said Ralph Brandenberger, PhD, Senior Vice President, Technical Operations. “GBF’s strong execution, along with their commitment to both quality and speed, enabled us to advance the development of NKX101 and dose patients in our Phase 1 clinical trial. We look forward to continuing our important collaboration.”

Find out more in the press release.

Categories: Ecosystem News